Karo Pharma, an EQT VIII portfolio company, has announced the acquisition of the remaining European rights to the Pevaryl brand portfolio from Cilag GmbH International, an affiliate of Johsnon & Johnson.
The acquisition consolidates the full ownership of the Peravyl brand portfolio with Karo Pharma. The portfolio generated net sales of approximately €20M in 2019.
Karo Pharma already commercializes and owns Gyno-Pevaryl , Epi – Pevaryl and Pevaryl in certain European markets.
The brand portfolio is available in more than 20 European countries with €30M in net sales. This acquisition adds scale and scope in new regions such as Italy as well as focus categories of intimate care and foot care.
Source: Karo Pharma
Apax Partners, the private equity investment group with headquarters in London, has scored a return multiple of over four times (4.2x) on the sale…
EQT AB is planning an initial public offering for German enterprise software developer SUSE. According to Bloomberg, the private equity firm would seek a…